The FDA Criticised for not Enforcing The Synthetic Nicotine Ban

Industry InsightRegulations
Jul.18.2022
After being criticised for not enforcing the synthetic nicotine ban, the FDA started sending warnings to non-authorized manufacturers and retailers of the products.

On July 13th the FDA announced that it sent two warning letters to manufacturers marketing non-authorized synthetic nicotine products and over 100 warning letters to retailers selling synthetic nicotine products to minors.

The FDA Criticised for not Enforcing The Synthetic Nicotine Ban

 

Synthetic products, which are often sold in fruity flavors and are popular with teens, have previously been exempt from FDA regulations because they are made from nicotine made in a lab, rather than nicotine extracted from tobacco leaf.

However, following a legislation enacted on March 15th, the US Food and Drug Administration (FDA) has been given the authority to regulate tobacco products containing nicotine from any source. This has led to a ban on synthetic nicotine.

 

After the passing of the synthetic nicotine ban, the Vapor Trade Association (VTA) immediately began working on a strategy to ensure a viable path for companies which are selling the products. Moreover, the VTA’s Board of Directors and members met with the FDA Center for Tobacco Products (CTP) to discuss the ban.

 

The FDA personnel in attendance included over 35 senior leaders, representing seven different offices inside CTP. The VTA held presentations by three Ph.D’s in Organic Chemistry and Physical Analytical Chemistry, in order to frame critical scientific and public policy issues that we believe had not previously been presented to or considered by the FDA.

 

Synthetic nicotine manufacturers had to submit premarket applications by May 14th

 

The March legislation required synthetic nicotine manufacturers to submit premarket applications by May 14, 2022, and any brand which had not submitted these documents would be considered illegal. However, until earlier this week this had never been enforced by the FDA.

 

Naturally this led to the agency being heavily criticised. In a letter, which cited STAT’s reporting on the agency’s lack of action, Senators Dick Durbin (D-Ill.) and Susan Collins (R-Maine), said that the FDA “appears to be on the brink of failing yet again at protecting our nation’s children.”

 

Meanwhile, on July 13th the FDA announced that it sent two warning letters to manufacturers marketing non-authorized synthetic nicotine products and over 100 warning letters to retailers who sold synthetic nicotine products to minors.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

 

 

Product | 22ml Combined E-Liquid Supply, Rated for 35,000 Puffs: OXBAR Launches the OX35K Open-System Pod Device
Product | 22ml Combined E-Liquid Supply, Rated for 35,000 Puffs: OXBAR Launches the OX35K Open-System Pod Device
The vaping brand OXBAR has recently listed its open-system, refillable pod device OX35K on its official website. The product features a “2ml built-in pod + two 10ml external refill bottles” e-liquid supply structure and supports top refilling, with a claimed puff count of up to 35,000. It is equipped with a 1000mAh built-in battery and offers dual power modes—BOOST and ECO—positioning the device to balance high-puff performance with an open-system form factor.
Jan.13 by 2FIRSTS.ai
Kumulus Vape launches Labster production unit for e-liquids and DIY concentrates
Kumulus Vape launches Labster production unit for e-liquids and DIY concentrates
Kumulus Vape has launched Labster, a 700 sq m production unit in the Lyon Metropolis near the group’s headquarters, for e-liquids and DIY concentrates. The site is equipped with automated lines supplied by CDA (Constructions d’Automatismes) to carry out bottling and labeling. Its theoretical capacity is described as several million bottles per year in 10–100 ml formats, and it is already operational.
Feb.06 by 2FIRSTS.ai
Walgreens Brings Vapes Back to Some U.S. Stores; Juul Says It’s in or Near 6,000 Locations
Walgreens Brings Vapes Back to Some U.S. Stores; Juul Says It’s in or Near 6,000 Locations
Walgreens has begun selling vape products again in some U.S. stores, marking a notable reversal after the chain pulled vapes from shelves in 2019 amid concerns over youth use and health risks. Juul says it is expanding across thousands of Walgreens locations, and NJOY also lists Walgreens stores as retailers.
Jan.26 by 2FIRSTS.ai
IQOS UK unveils 2026 pop-up events plan, first stops set for London and three other cities
IQOS UK unveils 2026 pop-up events plan, first stops set for London and three other cities
IQOS’ UK website shows the company will roll out time-limited pop-up experience spaces across Britain in 2026 for adult consumers. The first confirmed locations are London, the West Midlands area near Birmingham, Manchester and Romford, offering product demonstrations, pop-up-only promotions and nicotine pouch sampling. Entry will be restricted to those aged 18 and over, with “Challenge 25” ID checks in place.
Feb.03 by 2FIRSTS.ai
FRE Nicotine Pouches Partners with Taylor Reimer Racing, Covering Four 2026 ARCA Events
FRE Nicotine Pouches Partners with Taylor Reimer Racing, Covering Four 2026 ARCA Events
FRE® Nicotine Pouches announced a partnership with Taylor Reimer Racing, becoming the Official Nicotine Sponsor for four races in the 2026 ARCA Menards Series and serving as the primary sponsor at events in Alabama, Michigan, Minnesota, and Arizona. FRE branding will appear on the race car, driver suit, and helmet, and the collaboration will also extend to off-track content and activations.
Feb.27
The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past
The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past
As next-generation nicotine products become economically central rather than marginal, traditional volume-based metrics are increasingly unable to explain consumption, risk, and value. Units designed for a cigarette-based economy struggle to describe systems defined by delivery speed, pharmacokinetics, and adaptive user behavior. Drawing on financial reporting, regulation, and nicotine science, a fundamental question: can the future of nicotine still be measured using the tools of its past?
Feb.09 by Alan Zhao | 2Firsts Perspectives